Physician profile
Brian B Ibrahim
NPI 1891006490
$5,776.53
in general payments reported to CMS, 2019-2025
47 companies · $1,797 in 2025
The $1,797 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $932 · 2021: $461 · 2022: $756 · 2023: $935 · 2024: $896 · 2025: $1,797.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,628.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,627.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $755.67 | 2019-2025 | Aveir, Jot Dx |
| Pfizer INC. | $434.44 | 2021-2025 | |
| Amgen INC. | $416.25 | 2019-2025 | Repatha, Repatha, Otezla |
| Novo Nordisk INC | $379.13 | 2021-2025 | Ozempic, Rybelsus |
| Boston Scientific Corporation | $372.98 | 2021-2025 | Watchman Flx, Watchman |
| Exact Sciences Corporation | $279.41 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbvie INC. | $255.94 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $255.06 | 2022-2025 | Verquvo |
| Allergan, INC. | $237.57 | 2019 | |
| Novartis Pharmaceuticals Corporation | $230.82 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $205.18 | 2022-2025 | Jardiance |
| Amarin Pharma, INC. | $200.38 | 2021-2023 | |
| Madrigal Pharmaceuticals | $159.83 | 2025 | Rezdiffra |
| E.R. Squibb & Sons, L.L.C. | $126.18 | 2022-2025 | Eliquis, Camzyos |
| Sunovion Pharmaceuticals INC. | $123.66 | 2019 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $119.47 | 2023-2025 | Barostim Neo System |
| Astellas Pharma US INC | $117.51 | 2021-2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $105.70 | 2021-2023 | |
| Lilly USA, LLC | $78.33 | 2024 | Mounjaro, Zepbound, Jardiance |
| Kowa Pharmaceuticals America, INC. | $77.74 | 2021-2023 | Livalo, Seglentis |
| Janssen Pharmaceuticals, INC | $73.11 | 2022-2024 | Xarelto |
| Becton, Dickinson and Company | $72.33 | 2024 | Venclose Maven Catheter |
| Horizon Therapeutics Plc | $60.71 | 2023 | Krystexxa |
| Esperion Therapeutics, INC. | $55.47 | 2021-2025 | Nexletol |
| American Regent | $49.83 | 2024 | Injectafer |
| Glaxosmithkline, LLC. | $46.87 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Kiniksa Pharmaceuticals, LTD. | $41.85 | 2021-2022 | |
| Mylan Specialty L.P. | $41.09 | 2021 | |
| Bard Peripheral Vascular, INC. | $40.96 | 2025 | Venclose Maven Catheter |
| Medtronic, INC. | $33.61 | 2025 | Venaseal |
| Shield Therapeutics INC | $29.81 | 2024-2025 | |
| Scpharmaceuticals INC. | $24.42 | 2023 | |
| Medicure Pharma INC. | $24.27 | 2025 | Zypitamag |
| Lexicon Pharmaceuticals, INC. | $24.13 | 2023 | Inpefa |
| Kiniksa Pharmaceuticals International, Plc | $22.81 | 2024 | Arcalyst |
| Calliditas Therapeutics US INC. | $20.97 | 2023 | Tarpeyo |
| Alnylam Pharmaceuticals INC. | $19.70 | 2025 | Onpattro |
| Corcept Therapeutics | $18.27 | 2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $17.86 | 2021 | |
| Heartflow, INC. | $17.09 | 2025 | |
| Grifols USA, LLC | $16.94 | 2025 | Prolastin-C Liquid |
| Dexcom, INC. | $16.63 | 2025 | Dexcom G6 Transmitter |
| Acerus Pharmaceuticals Corporation | $16.60 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $15.99 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $15.92 | 2023 | Evkeeza |
| Paratek Pharmaceuticals, INC. | $14.23 | 2021 | |
| Currax Pharmaceuticals LLC | $13.81 | 2024 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Ibrahim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.